Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2

Biochimica et Biophysica Acta - General Subjects

Volumn 1850, Issue 6, 2015, Pages 1197-1205

  Hosokawa, Yuki ^a   Takahashi, Hisaaki ^a   Inoue, Akihiro ^a   Kawabe, Yuya ^a   Funahashi, Yu ^a   Kameda, Kenji ^b   Sugimoto, Kana ^c   Yano, Hajime ^a   Harada, Hironobu ^a   Kohno, Shohei ^a   Ohue, Shiro ^a   Ohnishi, Takanori ^a   Tanaka, Junya ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ABC transporter; Drug resistance; Glioblastoma; Oct 3 4

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OCTAMER TRANSCRIPTION FACTOR 4; PLACEBO; SHORT HAIRPIN RNA; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIMETABOLITE; POU5F1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STUDY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84923348001     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2015.01.017     Document Type: Article

References (42)

1. M. Khasraw, and A.B. Lassman Advances in the treatment of malignant gliomas Curr. Oncol. Rep. 12 2010 26 33
2. D.R. Johnson, and B.P. O'Neill Glioblastoma survival in the United States before and during the temozolomide era J. Neurooncol. 107 2012 359 364
3. I. Jovčevska, N. Kočevar, and R. Komel Glioma and glioblastoma - how much do we (not) know? Mol. Clin. Oncol. 1 2013 935 941
4. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, A. Jouvet, B.W. Scheithauer, and P. Kleihues The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol. 114 2007 97 109
5. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, and R.C. Janzer Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996
6. M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet, M. Weller, J.M. Kros, J.A. Hainfellner, W. Mason, L. Mariani, J.E. Bromberg, and P. Hau MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 352 2005 997 1003
7. G. Szakács, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
8. A.M. Bleau, J.T. Huse, and E.C. Holland The ABCG2 resistance network of glioblastoma Cell Cycle 8 2009 2936 2944
9. S. Jerabek, F. Merino, H.R. Schöler, and V. Cojocaru OCT4: dynamic DNA binding pioneers stem cell pluripotency Biochim. Biophys. Acta 2014 1839 138 154
10. T. Jin, D.R. Branch, X. Zhang, S. Qi, B. Youngson, and P.E. Goss Examination of POU homeobox gene expression in human breast cancer cells Int. J. Cancer 81 2009 104 112
11. Y. Atlasi, S.J. Mowla, S.A. Ziaee, and A.R. Bahrami OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer Int. J. Cancer 120 2007 1598 1602
12. S.H. Chiou, C.C. Yu, C.Y. Huang, S.C. Lin, C.J. Liu, T.H. Tsai, S.H. Chou, C.S. Chien, H.H. Ku, and J.F. Lo Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma Clin. Cancer Res. 14 2008 4085 4095
13. C.C. Chang, G.S. Shieh, P. Wu, C.C. Lin, A.L. Shiau, and C.L. Wu Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells Cancer Res. 68 2008 6281 6291
14. Q. Wang, W. He, C. Lu, Z. Wang, J. Wang, K.E. Giercksky, J.M. Nesland, and Z. Suo Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma Anticancer Res. 29 2009 1233 1241
15. Z. Du, D. Jia, S. Liu, F. Wang, G. Li, Y. Zhang, X. Cao, E.A. Ling, and A. Hao Oct4 is expressed in human gliomas and promotes colony formation in glioma cells Glia 57 2009 724 733
16. K. Hochedlinger, Y. Yamada, C. Beard, and R. Jaenisch Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues Cell 121 2005 465 477
17. D. Ponti, A. Costa, N. Zaffaroni, G. Pratesi, G. Petrangolini, D. Coradini, S. Pilotti, M.A. Pierotti, and M.G. Daidone Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties Cancer Res. 65 2005 5506 5511
18. Y.C. Chen, H.S. Hsu, Y.W. Chen, T.H. Tsai, C.K. How, C.Y. Wang, S.C. Hung, Y.L. Chang, M.L. Tsai, Y.Y. Lee, H.H. Ku, and S.H. Chiou Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells PLoS One 3 2008 e2637
19. C.E. Meacham, and S.J. Morrison Tumour heterogeneity and cancer cell plasticity Nature 501 2013 328 337
20. K.B. Pointer, P.A. Clark, M. Zorniak, B.M. Alrfaei, and J.S. Kuo Glioblastoma cancer stem cells: biomarker and therapeutic advances Neurochem. Int. 71C 2014 1 7
21. K. Kobayashi, H. Takahashi, A. Inoue, H. Harada, S. Toshimori, Y. Kobayashi, K. Goto, K. Sugimoto, H. Yano, T. Ohnishi, and J. Tanaka Oct-3/4 promotes migration and invasion of glioblastoma cells J. Cell. Biochem. 113 2012 508 517
22. H. Hino, H. Takahashi, Y. Suzuki, J. Tanaka, E. Ishii, and M. Fukuda Anticonvulsive effect of paeoniflorin on experimental febrile seizures in immature rats: possible application for febrile seizures in children PLoS One 7 2012 e42920
23. M. Tewari, L.T. Quan, K. O'Rourke, S. Desnoyers, Z. Zeng, D.R. Beidler, G.G. Poirier, G.S. Salvesen, and V.M. Dixit Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase Cell 81 1995 801 809
24. P. Krishnamurthy, D.D. Ross, T. Nakanishi, K. Bailey-Dell, S. Zhou, K.E. Mercer, B. Sarkadi, B.P. Sorrentino, and J.D. Schuetz The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme J. Biol. Chem. 279 2004 24218 24225
25. H. Zhong, K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M.M. Georgescu, J.W. Simons, and G.L. Semenza Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics Cancer Res. 60 2000 1541 1545
26. L. Zhang, N. Yang, D. Katsaros, W. Huang, J.W. Park, S. Fracchioli, C. Vezzani, I.A. Rigault de la Longrais, W. Yao, S.C. Rubin, and G. Coukos The oncogene phosphatidylinositol 3′-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma Cancer Res. 63 2003 4225 4231
27. C. Xia, Q. Meng, Z. Cao, X. Shi, and B.H. Jiang Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression J. Cell. Physiol. 209 2006 56 66
28. H. Takahashi, A. Inoue, Y. Kawabe, Y. Hosokawa, S. Iwata, K. Sugimoto, H. Yano, D. Yamashita, H. Harada, S. Kohno, S. Ohue, T. Ohnishi, and J. Tanaka Oct-3/4 promotes tumor angiogenesis through VEGF production in glioblastoma Brain Tumor Pathol. 32 2015 31 40
29. A.M. Bleau, D. Hambardzumyan, T. Ozawa, E.I. Fomchenko, J.T. Huse, C.W. Brennan, and E.C. Holland PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells Cell Stem Cell 4 2009 226 235
30. D.S. Marques, J.Z. Sandrini, R.T. Boyle, L.F. Marins, and G.S. Trindade Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines Leuk. Res. 34 2010 757 762
31. X.Q. Wang, W.M. Ongkeko, L. Chen, Z.F. Yang, P. Lu, K.K. Chen, J.P. Lopez, R.T. Poon, and S.T. Fan Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway Hepatology 52 2010 528 539
32. D.E. Linn, X. Yang, F. Sun, Y. Xie, H. Chen, R. Jiang, H. Chen, S. Chumsri, A.M. Burger, and Y. Qiu A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells Genes Cancer 1 2010 908 916
33. L.L. Tsai, C.C. Yu, Y.C. Chang, C.H. Yu, and M.Y. Chou Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma J. Oral Pathol. Med. 40 2011 621 628
34. C.A. Iacobuzio-Donahue Epigenetic changes in cancer Annu. Rev. Pathol. 4 2009 229 249
35. N. Bhutani, J.J. Brady, M. Damian, A. Sacco, S.Y. Corbel, and H.M. Blau Reprogramming towards pluripotency requires AID-dependent DNA demethylation Nature 463 2010 1042 1047
36. A. Inoue, H. Takahashi, H. Harada, S. Kohno, S. Ohue, K. Kobayashi, H. Yano, J. Tanaka, and T. Ohnishi Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity Int. J. Oncol. 37 2010 1121 1131
37. C.T. Jordan, M.L. Guzman, and M. Noble Cancer stem cells N. Engl. J. Med. 355 2006 1253 1261
38. B.B. Zhou, H. Zhang, M. Damelin, K.G. Geles, J.C. Grindley, and P.B. Dirks Tumour-initiating cells: challenges and opportunities for anticancer drug discovery Nat. Rev. Drug Discov. 8 2009 806 823
39. Y. Guo, C. Mantel, R.A. Hromas, and H.E. Broxmeyer Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin Stem Cells 26 2008 30 34
40. E. Monzani, F. Facchetti, E. Galmozzi, E. Corsini, A. Benetti, C. Cavazzin, A. Gritti, A. Piccinini, D. Porro, M. Santinami, G. Invernici, E. Parati, G. Alessandri, and C.A. La Porta Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential Eur. J. Cancer 43 2007 935 946
41. C. La Porta Cancer stem cells: lessons from melanoma Stem Cell Rev. 5 2009 61 65
42. C. Wu, and B.A. Alman Side population cells in human cancers Cancer Lett. 268 2008 1 9